Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — FY2020 Earnings Presentation
13 slides from Vita Life Sciences's earnings presentation, Feb 22, 2021
Slide 1: Financial Results for the Year Ended 31 December 2020
FINANCIAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020 22 Feb 2021 23Feb2021
Slide 2: Business Overview: Vita Life Sciences
Page 1 BUSINESS VITA LIFE SCIENCES OVERVIEW • Australian and Asia Pacific based pharmaceutical and healthcare over-the- counter vitamins and supplements business: formulation, packaging, distribution and sale of 3 major consumer retail brands • Over 700 registered vitamins and supplement products (S
Slide 3: Group Sales and EBIT Commentary
Page 2 GROUP SALES A$’m COMMENTARY 48 46 44 • Record Group sales of $46.5m, up 9% on previous 42 corresponding period reflecting the impact of increased 40 channels of distribution and stronger consumer demand for complementary medicine. 38 Full Year • Covid -19 increased the demand for Immunity pro
Slide 4: Australia and Malaysia
Page 3 AUSTRALIA MALAYSIA Record revenue of $20.8m an increase of 25% on previous Record revenue of $16.9m an increase of 8% on PCP. corresponding period (PCP). Increased demand domestically for both VitaHealth and Herbs of Domestic sales were strong with 16% growth on PCP. Gold brands under
Slide 5: Singapore and Other Asia
Page 4 SINGAPORE OTHER ASIA Revenue of $ 3.9m a reduction of 9% on PCP. Covid-19 related Revenue of $4.9m a decrease of 17% on PCP due to the challenging trading conditions following Covid-19. trading conditions across Vietnam, Thailand and Indonesia influenced the performance. Government orde
Slide 6: Final Dividend & Cashflows
Page 5 FINAL DIVIDEND & Gross operating cashflow to EBITDA CASHFLOWS 120% 100% 80% • Increase in gross operating cashflow conversion to EBITDA of 105% mainly due to higher sales, lower 60% marketing investments, overheads and timing of 40% payments 20% 0% Full Year • Fully franked final dividend dec
Slide 7: Priorities & Outlook
Page 6 PRIORITIES & OUTLOOK • Implement a new 3-year brand building investment strategy that drives higher consumer and retailer engagement. • Execute an educational and digitally led marketing strategy which support the brands premium product positioning. • Leverage the Groups brand portfolio to dr
Slide 8: Appendix
Page7 APPENDIX
Slide 9: Full Year Results
Page 8 FULL YEAR RESULTS Full year ended Dec 2020 2019 $’m $’m Revenue 46.5 42.4 EBITDA 8.7 5.0 EBIT 8.1 4.4 Profit before tax 8.1 4.4 Profit after tax 5.9 3.1 EPS (Basic – cents/ share) 11.58 5.73 Dividend (cents / share) 4.25 3.75
Slide 10: Balance Sheet
Page 9 BALANCE SHEET Balance Sheet as at Dec 2020 2019 $’m $’m Current assets 29.2 25.8 Non-current assets 9.9 10.7 Total assets 39.1 36.5 Current liabilities 13.0 12.1 Non-current liabilities 1.7 1.9 Total Liabilities 14.7 14.0 Net Assets 24.4 22.5
Slide 11: Cash Flow
Page 10 CASH FLOW Cash Flow for the year ended Dec 2020 2019 $’m $’m Receipts from customers 50.2 45.1 Payments to suppliers and employees (41.1) (41.2) Gross operating cash flow 9.1 3.9 EBITDA 8.7 5.0 Gross operating cash flow / EBITDA 104.6% 76.8% Net interest 0 0 Income tax paid (1.7) (1.8) Opera
Slide 12: Contact
Page 11 CONTACT Contact: Mr Chin L Khoo, CFO: 0450 734 526 Mr Andrew O’Keefe, Managing Director: 0448 882 556 Office Telephone : +61 2 9545 2633 Website: vitalifesciences.com.au Email: enquiries@vitalifesciences.com.au Head Office: 1/ 102 Bath Road, Kirrawee, NSW 2232, AUSTRALIA
Slide 13: Disclaimer
Page 12 DISCLAIMER This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any offer or invitat